scholarly journals Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Håkan Ashina ◽  
Afrim Iljazi ◽  
Haidar Muhsen Al-Khazali ◽  
Anna Kristina Eigenbrodt ◽  
Eigil Lindekilde Larsen ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Mild Traumatic Brain Injury ◽  
Preventive Treatment ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Post Traumatic

Open-label study of donepezil in traumatic brain injury

2001 ◽  
Vol 82 (7) ◽  
pp. 896-901 ◽  
Author(s):  
Cheryl A. Masanic ◽  
Mark T. Bayley ◽  
Robert vanReekum ◽  
Martine Simard
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury

BMC Neurology ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Flora M. Hammond ◽  
David N. Alexander ◽  
Andrew J. Cutler ◽  
Stephen D’Amico ◽  
Rachelle S. Doody ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Pseudobulbar Affect

scholarly journals Efficacy, Tolerability, and Safety of Erenumab for the Preventive Treatment of Persistent Post-Traumatic Headache attributed to Mild Traumatic Brain Injury: An Open-Label Study.

2020 ◽  
Author(s):  
Håkan Ashina ◽  
Afrim Iljazi ◽  
Haidar Al-Khazali ◽  
Anna Kristina Eigenbrodt ◽  
Eigil Larsen ◽  
...  
Keyword(s):  
Adverse Events ◽  
Randomized Clinical Trials ◽  
Preventive Treatment ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Severe Intensity ◽  
Post Traumatic ◽  
The Mean ◽  
Open Label Trial

Abstract BackgroundCalcitonin gene-related peptide (CGRP) has recently been implicated in the pathogenesis of post-traumatic headache (PTH), which raises the prospect for therapeutic use of monoclonal antibodies targeting CGRP or its receptor. Therefore, we decided to assess the efficacy, tolerability, and safety of erenumab for prevention of persistent PTH attributed to mild traumatic brain injury.MethodsA single-center, non-randomized, single-arm, open-label study of erenumab for adults aged 18–65 years with persistent PTH. Patients were assigned to receive 140-mg erenumab monthly by two subcutaneous 1-mL injections, given every 4 weeks for 12 weeks. The primary outcome measure was the mean change in number of monthly headache days of moderate to severe intensity from baseline (4-week pretreatment period) to week 9 through 12. Tolerability and safety endpoints were adverse events (i.e. number and type).ResultsEighty-nine of 100 patients completed the open-label trial. At baseline, the mean monthly number of headache days of moderate to severe intensity was 15.7. By week 9 through 12, the number was reduced by 2.8 days. The most common adverse events were constipation (n = 30) and injection-site reactions (n = 15). Of 100 patients who received at least one dose of erenumab, only two discontinued the treatment regimen due to adverse events.ConclusionsAmong patients with persistent PTH, erenumab resulted in a lower frequency of moderate to severe headache days in this 12-week open-label trial. In addition, erenumab was well-tolerated as discontinuations due to adverse events were low. Placebo-controlled randomized clinical trials are needed to adequately evaluate the efficacy and safety of erenumab in persistent PTH.Trial RegistrationClinicalTrials.Gov, NCT03974360. Registered on April 17, 2019 - Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03974360

scholarly journals Dextromethorphan-quinidine is helpful for pseudobulbar affect disorder in stroke patients

2021 ◽  
Vol 7 (2) ◽  
Author(s):  
Michael Francis ◽  
Mira Hamame ◽  
Mariam Nasrallah ◽  
Alison Nesbitt ◽  
James P. Meza
Keyword(s):  
Traumatic Brain Injury ◽  
Informed Consent ◽  
Brain Injury ◽  
Stroke Patients ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Pseudobulbar Affect

An informed consent article using Hammond FM, Alexander DN, Cutler AJ, et al. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMC Neurology. 2016;16:89. https://doi.org/10.1186/s12883-016-0609-0 for a patient with pseudobulbar affect following stroke.

An open-label study of citalopram for major depression following traumatic brain injury

2008 ◽  
Vol 22 (8) ◽  
pp. 860-864 ◽  
Author(s):  
MJ Rapoport ◽  
F. Chan ◽  
K. Lanctot ◽  
N. Herrmann ◽  
S. McCullagh ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Major Depression ◽  
Open Label ◽  
Open Label Study ◽  
Label Study
Sign in / Sign up

Export Citation Format

Share Document